<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ITRACONAZOLE- itraconazole capsule </strong><br>Patriot Pharmaceuticals<br></p></div>
<h1>Itraconazole Capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">PATRIOT<br>Pharmaceuticals</span></p>
<p><span class="Bold">Itraconazole<br>Capsules</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1>BOXED WARNING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>, Cardiac Effects and Drug Interactions</h2>
<p class="First"><span class="Bold">Itraconazole Capsules should not be administered for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF. </span>If signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occur during administration of Itraconazole Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>,<a href="#WARNINGS"> WARNINGS</a>,<a href="#DI"> PRECAUTIONS: Drug Interactions</a>, <a href="#AR_pme">ADVERSE REACTIONS: Post-marketing Experience</a>, and <a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations</a> for more information.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="BOX_DI"></a><a name="section-2.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Bold">Coadministration of the following drugs are contraindicated with Itraconazole Capsules: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin,  ticagrelor and, in subjects with varying degrees of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, colchicine, fesoterodine, telithromycin and solifenacin. See <a href="#DI">PRECAUTIONS: Drug Interactions</a> Section for specific examples. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> including occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. See<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a> and <a href="#WARNINGS"> WARNINGS</a> Sections, and<a href="#DI"> PRECAUTIONS: Drug Interactions </a>Section for specific examples.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Itraconazole is an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the following structural formula and nomenclature:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6242b7ad-eaa0-a524-b6e0-ec33e63407db&amp;name=itraconazole-01.jpg"></div>
<p>(±)-1-[(<span class="Underline">R</span>*)-<span class="Underline">sec</span>-butyl]-4-[<span class="Underline">p</span>-[4-[<span class="Underline">p</span>-[[(2<span class="Underline">R</span>*,4<span class="Underline">S</span>*)-2-(2,4-dichlorophenyl)-2-(1<span class="Underline">H</span>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<span class="Sup">2</span>-1,2,4-triazolin-5-one mixture with (±)-1-[(<span class="Underline">R</span>*)-<span class="Underline">sec</span>-butyl]-4-[<span class="Underline">p</span>-[4-[<span class="Underline">p</span>-[[(2<span class="Underline">S</span>*,4<span class="Underline">R</span>*)-2-(2,4-dichlorophenyl)-2-(1<span class="Underline">H</span>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<span class="Sup">2</span>-1,2,4-triazolin-5-one</p>
<p>or</p>
<p>(±)-1-[(<span class="Underline">RS</span>)-<span class="Underline">sec</span>-butyl]-4-[<span class="Underline">p</span>-[4-[<span class="Underline">p</span>-[[(2<span class="Underline">R</span>,4<span class="Underline">S</span>)-2-(2,4-dichlorophenyl)-2-(1<span class="Underline">H</span>-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<span class="Sup">2</span>-1,2,4-triazolin-5-one</p>
<p>Itraconazole has a molecular formula of C<span class="Sub">35</span>H<span class="Sub">38</span>Cl<span class="Sub">2</span>N<span class="Sub">8</span>O<span class="Sub">4</span> and a molecular weight of 705.64. It is a white to slightly yellowish powder. It is insoluble in water, very slightly soluble in alcohols, and freely soluble in dichloromethane. It has a pKa of 3.70 (based on extrapolation of values obtained from methanolic solutions) and a log (n-octanol/water) partition coefficient of 5.66 at pH 8.1.</p>
<p>Itraconazole Capsules contain 100 mg of itraconazole coated on sugar spheres (composed of sucrose, maize starch, and purified water). Inactive ingredients are hard gelatin capsule, hypromellose, polyethylene glycol (PEG) 20,000, titanium dioxide, FD&amp;C Blue No. 1, FD&amp;C Blue No. 2, D&amp;C Red No. 22 and D&amp;C Red No. 28.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>General Pharmacokinetic Characteristics</h3>
<p class="First">Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing. Steady-state concentrations are generally reached within about 15 days, with C<span class="Sub">max</span> values of 0.5 µg/mL, 1.1 µg/mL and 2.0 µg/mL after oral administration of 100 mg once daily, 200 mg once daily and 200 mg b.i.d., respectively. The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. Itraconazole mean total plasma clearance following intravenous administration is 278 mL/min. Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Absorption</h3>
<p class="First">Itraconazole is rapidly absorbed after oral administration. Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following an oral capsule dose. The observed absolute oral bioavailability of itraconazole is about 55%.</p>
<p>The oral bioavailability of itraconazole is maximal when Itraconazole Capsules are taken immediately after a full meal.</p>
<p>Absorption of itraconazole capsules is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as gastric acid secretion suppressors (e.g., H<span class="Sub">2</span>-receptor antagonists, proton pump inhibitors) or subjects with <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span> caused by certain diseases. (See <a href="#DI">PRECAUTIONS: Drug Interactions</a>.) Absorption of itraconazole under fasted conditions in these subjects is increased when Itraconazole Capsules are administered with an acidic beverage (such as a non-diet cola). When Itraconazole Capsules were administered as a single 200-mg dose under fasted conditions with non-diet cola after ranitidine pretreatment, a H<span class="Sub">2</span>-receptor antagonist, itraconazole absorption was comparable to that observed when Itraconazole Capsules were administered alone. (See <a href="#DI">PRECAUTIONS: Drug Interactions</a>.)</p>
<p>Itraconazole exposure is lower with the Capsule formulation than with the Oral Solution when the same dose of drug is given. (See <a href="#WARNINGS">WARNINGS</a>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">Most of the itraconazole in plasma is bound to protein (99.8%), with albumin being the main binding component (99.6% for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (&gt;700 L), suggesting extensive distribution into tissues.  Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Itraconazole is extensively metabolized by the liver into a large number of metabolites. <span class="Italics">In vitro</span> studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole. The main metabolite is hydroxy-itraconazole, which has <span class="Italics">in vitro</span> antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>Excretion</h3>
<p class="First">Itraconazole is excreted mainly as inactive metabolites in urine (35%) and in feces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabeled dose, fecal excretion of unchanged drug ranges from 3% to 18% of the dose.</p>
<p>As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CP_SP"></a><a name="section-3.2"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. A pharmacokinetic study using a single 200-mg oral dose of itraconazole was conducted in three groups of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13 mL/min. × 1.73 m<span class="Sup">2</span>, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (T<span class="Sub">max</span>, C<span class="Sub">max</span>, and AUC<span class="Sub">0–8h</span>). Plasma concentration-versus-time profiles showed wide intersubject variation in all three groups. After a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as CrCl 50–79 mL/min), moderate (defined in this study as CrCl 20–49 mL/min), and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined in this study as CrCl &lt;20 mL/min) were similar to that in healthy subjects (range of means 42–49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> by approximately 30% and 40%, respectively, as compared with subjects with normal renal function. Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the half-life or clearance of itraconazole or hydroxy-itraconazole. (See<a href="#PRECAUTIONS"> PRECAUTIONS </a>and<a href="#DA"> DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">Itraconazole is predominantly metabolized in the liver. A pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100-mg dose of itraconazole as capsule. A statistically significant reduction in mean C<span class="Sub">max</span> (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole. (See<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#DI"> PRECAUTIONS: Drug Interactions </a>and<a href="#DA"> DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Decreased Cardiac Contractility</h3>
<p class="First">When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> appear during administration of Itraconazole Capsules, itraconazole should be discontinued. (See <a href="#BOX">BOXED WARNING</a>,<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#WARNINGS"> WARNINGS</a>,<a href="#DI"> PRECAUTIONS: Drug Interactions </a>and<a href="#AR_pme"> ADVERSE REACTIONS: Post-marketing Experience </a>for more information.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="MICROBIOLOGY"></a><a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-4.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First"><span class="Italics">In vitro </span>studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Activity<span class="Italics"> In Vitro </span>and in Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Itraconazole exhibits <span class="Italics">in vitro</span> activity against <span class="Italics">Blastomyces dermatitidis, Histoplasma capsulatum, Histoplasma duboisii, Aspergillus flavus, Aspergillus fumigatus, and Trichophyton</span> species (See <a href="#docs"> INDICATIONS AND USAGE, Description of Clinical Studies</a>).</p>
<p>Correlation between <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) results <span class="Italics">in vitro</span> and clinical outcome has yet to be established for azole antifungal agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">Isolates from several fungal species with decreased susceptibility to itraconazole have been isolated <span class="Italics">in vitro</span> and from patients receiving prolonged therapy.</p>
<p>Itraconazole is not active against <span class="Italics">Zygomycetes</span> (e.g., <span class="Italics">Rhizopus</span> spp., <span class="Italics">Rhizomucor s</span>pp., <span class="Italics">Mucor</span> spp. and <span class="Italics">Absidia</span> spp.), <span class="Italics">Fusarium</span> spp., <span class="Italics">Scedosporium</span> spp. and <span class="Italics">Scopulariopsis</span> spp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Cross-resistance</h2>
<p class="First">Several <span class="Italics">in vitro</span> studies have reported that some fungal clinical isolates with reduced susceptibility to one azole antifungal agent may also be less susceptible to other azole derivatives. The finding of cross-resistance is dependent on a number of factors, including the species evaluated, its clinical history, the particular azole compounds compared, and the type of susceptibility test that is performed.</p>
<p>Studies (both<span class="Italics"> in vitro </span>and<span class="Italics"> in vivo</span>) suggest that the activity of amphotericin B may be suppressed by prior azole antifungal therapy. As with other azoles, itraconazole inhibits the <span class="Sup">14</span>C-demethylation step in the synthesis of ergosterol, a cell wall component of fungi. Ergosterol is the active site for amphotericin B. In one study the antifungal activity of amphotericin B against<span class="Italics"> Aspergillus fumigatus </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in mice was inhibited by ketoconazole therapy. The clinical significance of test results obtained in this study is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Itraconazole Capsules are indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in <span class="Underline">immunocompromised and non-immunocompromised</span> patients:</p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">Blastomycosis</span>, pulmonary and extrapulmonary</li>
<li><span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">Histoplasmosis</span>, including chronic cavitary pulmonary disease and disseminated, non-meningeal <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, and</li>
<li><span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span>, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.</li>
</ol>
<p>Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly.</p>
<p>Itraconazole Capsules are also indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in <span class="Underline">non-immunocompromised</span> patients:</p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the toenail, with or without fingernail involvement, due to dermatophytes (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium), and</li>
<li><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the fingernail due to dermatophytes (<span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium).</li>
</ol>
<p>Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>.</p>
<p>(See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations</a>,<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#WARNINGS"> WARNINGS</a>, and<a href="#AR_pme"> ADVERSE REACTIONS: Post-marketing Experience </a>for more information.)</p>
<div class="Section" data-sectionCode="34092-7">
<a name="docs"></a><a name="section-5.1"></a><p></p>
<h2>Description of Clinical Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">Blastomycosis</span></h3>
<p class="First">Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span> compared with the natural history of untreated cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">Histoplasmosis</span></h3>
<p class="First">Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, compared with the natural history of untreated cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">Histoplasmosis</span> in HIV-infected patients</h3>
<p class="First">Data from a small number of HIV-infected patients suggested that the response rate of <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span> in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span> in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span></h3>
<p class="First">Analyses were conducted on data from an open-label, "single-patient-use" protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span> compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the toenail</h3>
<p class="First">Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given Itraconazole Capsules) in which patients with <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the toenails received 200 mg of Itraconazole Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the fingernail</h3>
<p class="First">Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given Itraconazole Capsules) in which patients with <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> of the fingernails received a 1-week course (pulse) of 200 mg of Itraconazole Capsules b.i.d., followed by a 3-week period without Itraconazole Capsules, which was followed by a second 1-week pulse of 200 mg of Itraconazole Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">Itraconazole Capsules should not be administered for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF. (See <a href="#BOX">BOXED WARNING</a>,<a href="#WARNINGS"> WARNINGS</a>, PRECAUTIONS: Drug Interactions-Calcium Channel Blockers, <a href="#AR_pme">ADVERSE REACTIONS: Post-marketing Experience</a>, and <a href="#CP_SP">CLINICAL PHARMACOLOGY: Special Populations</a>.)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="con_DI"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor,  and, in subjects with varying degrees of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, colchicine, fesoterodine, telithromycin and solifenacin. (See <a href="#DI">PRECAUTIONS: Drug Interactions</a> Section for specific examples.)  This increase in drug concentrations caused by coadministration with itraconazole, may increase or prolong both the pharmacologic effect and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> including occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Specific examples are listed in PRECAUTIONS: Drug Interactions.</p>
<p>Itraconazole should not be administered for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> to pregnant patients or to women contemplating pregnancy.</p>
<p>Itraconazole is contraindicated for patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to itraconazole. There is limited information regarding cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> between itraconazole and other azole antifungal agents. Caution should be used when prescribing itraconazole to patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other azoles.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="war_he"></a><a name="section-7.1"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First"><span class="Bold">Itraconazole has been associated with rare cases of serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition, and some of these cases developed within the first week of treatment. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. Continued itraconazole use or reinstitution of treatment with itraconazole is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. (See<a href="#Information"> PRECAUTIONS: Information for Patients </a>and<a href="#AR"> ADVERSE REACTIONS</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Dysrhythmias</span></h2>
<p class="First">Life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred in patients using drugs such as cisapride, pimozide, methadone, or quinidine concomitantly with itraconazole and/or other CYP3A4 inhibitors. Concomitant administration of these drugs with itraconazole is contraindicated. (See<a href="#BOX"> BOXED WARNING</a>,<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>, and<a href="#DI"> PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Cardiac Disease</h2>
<p class="First"><span class="Bold">Itraconazole Capsules should not be administered for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> in patients with evidence of ventricular dysfunction such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) or a history of CHF</span>. Itraconazole Capsules should not be used for other indications in patients with evidence of ventricular dysfunction unless the benefit clearly outweighs the risk.</p>
<p>For patients with risk factors for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, physicians should carefully review the risks and benefits of itraconazole therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and other edematous disorders. Such patients should be informed of the signs and symptoms of CHF, should be treated with caution, and should be monitored for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear during administration of Itraconazole Capsules, discontinue administration.</p>
<p>Itraconazole has been shown to have a negative inotropic effect. When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later.</p>
<p>Itraconazole has been associated with reports of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. In post-marketing experience, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> was more frequently reported in patients receiving a total daily dose of 400 mg although there were also cases reported among those receiving lower total daily doses.</p>
<p>Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF. Concomitant administration of itraconazole and felodipine or nisoldipine is contraindicated.</p>
<p>Cases of CHF, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> have been reported in the post-marketing period among patients being treated for <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> and/or systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations</a>,<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#DI"> PRECAUTIONS: Drug Interactions</a>, and<a href="#AR_pme"> ADVERSE REACTIONS: Post-marketing Experience </a>for more information.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Interaction potential</h2>
<p class="First">Itraconazole has a potential for clinically important drug interactions. Coadministration of specific drugs with itraconazole may result in changes in efficacy of itraconazole and/or the coadministered drug, life-threatening effects and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Drugs that are contraindicated, not recommended or recommended for use with caution in combination with itraconazole are listed in <a href="#DI">PRECAUTIONS: Drug Interactions</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Interchangeability</h2>
<p class="First">Itraconazole Capsules and SPORANOX<span class="Sup">®</span> (itraconazole) Oral Solution should not be used interchangeably. This is because drug exposure is greater with the Oral Solution than with the Capsules when the same dose of drug is given. In addition, the topical effects of mucosal exposure may be different between the two formulations. Only the Oral Solution has been demonstrated effective for oral and/or <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Itraconazole Capsules should be administered after a full meal. (See<a href="#Pharmacokinetics"> CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism</a>).</p>
<p>Under fasted conditions, itraconazole absorption was decreased in the presence of decreased gastric acidity. The absorption of itraconazole may be decreased with the concomitant administration of antacids or gastric acid secretion suppressors. Studies conducted under fasted conditions demonstrated that administration with 8 ounces of a non-diet cola beverage resulted in increased absorption of itraconazole in AIDS patients with relative or absolute <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span>. This increase relative to the effects of a full meal is unknown. (See<a href="#Pharmacokinetics"> CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="pre_Hepatotoxicity"></a><a name="section-8.2"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Rare cases of serious hepatotoxicity have been observed with itraconazole treatment, including some cases within the first week. It is recommended that liver function monitoring be considered in all patients receiving itraconazole. Treatment should be stopped immediately and liver function testing should be conducted in patients who develop signs and symptoms suggestive of liver dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> occurs that may be attributable to Itraconazole Capsules, the treatment should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span></h2>
<p class="First">If a <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patient does not respond to Itraconazole Capsules, consideration should be given to switching to alternative therapy. For more information concerning the use of itraconazole in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients see the prescribing information for SPORANOX<span class="Sup">®</span> Oral Solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></h2>
<p class="First">Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see<a href="#BOX_DI"> BOXED WARNING: Drug Interactions</a>,<a href="#con_DI"> CONTRAINDICATIONS: Drug Interactions </a>and<a href="#DI"> PRECAUTIONS: Drug Interactions</a>). The <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> usually resolves when treatment is stopped, but can persist in some patients.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Information"></a><a name="section-8.6"></a><p></p>
<h2>Information for Patients</h2>
<ul class="Disc">
<li>The topical effects of mucosal exposure may be different between Itraconazole Capsules and SPORANOX<span class="Sup">®</span> (itraconazole) Oral Solution. Only the Oral Solution has been demonstrated effective for oral and/or <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>. Itraconazole Capsules should not be used interchangeably with SPORANOX<span class="Sup">®</span> Oral Solution.</li>
<li>Instruct patients to take Itraconazole Capsules with a full meal. Itraconazole Capsules must be swallowed whole.</li>
<li>Instruct patients about the signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and if these signs or symptoms occur during itraconazole administration, they should discontinue itraconazole and contact their healthcare provider immediately.</li>
<li>Instruct patients to stop itraconazole treatment immediately and contact their healthcare provider if any signs and symptoms suggestive of liver dysfunction develop. Such signs and symptoms may include unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools.</li>
<li>Instruct patients to contact their physician before taking any concomitant medications with itraconazole to ensure there are no potential drug interactions.</li>
<li>Instruct patients that <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> can occur with the use of itraconazole. The <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> usually resolves when treatment is stopped, but can persist in some patients. Advise patients to discontinue therapy and inform their physicians if any <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> symptoms occur.</li>
<li>Instruct patients that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or blurred/<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span> can sometimes occur with itraconazole. Advise patients that if they experience these events, they should not drive or use machines.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-8.7"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Itraconazole is mainly metabolized through CYP3A4. Other drugs that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Similarly, itraconazole may modify the pharmacokinetics of other drugs that share this metabolic pathway. Itraconazole is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor. When using concomitant medication, it is recommended that the corresponding label be consulted for information on the route of metabolism and the possible need to adjust dosages.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="decrease"></a><a name="section-8.7.1"></a><p></p>
<h3>Drugs that may decrease itraconazole plasma concentrations</h3>
<p class="First">Drugs that reduce the gastric acidity (e.g. acid neutralizing medicines such as aluminum hydroxide, or acid secretion suppressors such as H<span class="Sub">2</span>-receptor antagonists and proton pump inhibitors) impair the absorption of itraconazole from Itraconazole Capsules. It is recommended that these drugs be used with caution when coadministered with Itraconazole Capsules:</p>
<ul class="Disc">
<li>It is recommended that itraconazole capsules be administered with an acidic beverage (such as non-diet cola) upon co-treatment with drugs reducing gastric acidity.</li>
<li>It is recommended that acid neutralizing medicines (e.g. aluminum hydroxide) be administered at least 1 hour before or 2 hours after the intake of Itraconazole Capsules.</li>
<li>Upon coadministration, it is recommended that the antifungal activity be monitored and the itraconazole dose increased as deemed necessary.</li>
</ul>
<p>Coadministration of itraconazole with potent enzyme inducers of CYP3A4 may decrease the bioavailability of itraconazole and hydroxy-itraconazole to such an extent that efficacy may be reduced. Examples include:</p>
<ul class="Disc">
<li>Antibacterials: isoniazid, rifabutin (see also under '<a href="#increasedby">Drugs that may have their plasma concentrations increased by itraconazole</a>'), rifampicin</li>
<li>Anticonvulsants: carbamazepine, (see also under '<a href="#increasedby">Drugs that may have their plasma concentrations increased by itraconazole</a>'), phenobarbital, phenytoin</li>
<li>Antivirals: efavirenz, nevirapine</li>
</ul>
<p>Therefore, administration of potent enzyme inducers of CYP3A4 with itraconazole is not recommended. It is recommended that the use of these drugs be avoided from 2 weeks before and during treatment with itraconazole, unless the benefits outweigh the risk of potentially reduced itraconazole efficacy. Upon coadministration, it is recommended that the antifungal activity be monitored and the itraconazole dose increased as deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="increase"></a><a name="section-8.7.2"></a><p></p>
<h3>Drugs that may increase itraconazole plasma concentrations</h3>
<p class="First">Potent inhibitors of CYP3A4 may increase the bioavailability of itraconazole. Examples include:</p>
<ul class="Disc">
<li>Antibacterials: ciprofloxacin, clarithromycin, erythromycin</li>
<li>Antivirals: ritonavir-boosted darunavir, ritonavir-boosted fosamprenavir, indinavir (see also under '<a href="#increasedby">Drugs that may have their plasma concentrations increased by itraconazole</a>'), ritonavir (see also under '<a href="#increasedby">Drugs that may have their plasma concentrations increased by itraconazole</a>') and telaprevir.</li>
</ul>
<p>It is recommended that these drugs be used with caution when coadministered with Itraconazole Capsules. It is recommended that patients who must take itraconazole concomitantly with potent inhibitors of CYP3A4 be monitored closely for signs or symptoms of increased or prolonged pharmacologic effects of itraconazole, and the itraconazole dose be decreased as deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="increasedby"></a><a name="section-8.7.3"></a><p></p>
<h3>Drugs that may have their plasma concentrations increased by itraconazole</h3>
<p class="First">Itraconazole and its major metabolite, hydroxy-itraconazole, can inhibit the metabolism of drugs metabolized by CYP3A4 and can inhibit the drug transport by P-glycoprotein, which may result in increased plasma concentrations of these drugs and/or their active metabolite(s) when they are administered with itraconazole. These elevated plasma concentrations may increase or prolong both therapeutic and adverse effects of these drugs. CYP3A4-metabolized drugs known to prolong the QT interval may be contraindicated with itraconazole, since the combination may lead to <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> including occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. In patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> or in subjects receiving CYP3A4 inhibitors, the decline in plasma concentrations may be even more gradual. This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole.</p>
<p>Examples of drugs that may have their plasma concentrations increased by itraconazole presented by drug class with advice regarding coadministration with itraconazole:</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1:	Drugs that may have their plasma concentrations increased by itraconazole</span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="22%">
<col align="left" valign="top" width="24%">
<col align="left" valign="top" width="24%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Drug Class</th>
<th class="Rrule" align="left">Contraindicated</th>
<th class="Rrule" align="left">Not Recommended</th>
<th class="Rrule" align="left">Use with Caution</th>
<th class="Rrule" align="left">Comments</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="Italics">Under no circumstances is the drug to be coadministered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.</span></td>
<td class="Rrule" align="left"><span class="Italics">It is recommended that the use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If coadministration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</span></td>
<td class="Rrule" align="left"><span class="Italics">Careful monitoring is recommended when the drug is coadministered with itraconazole. Upon coadministration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alpha Blockers</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">tamsulosin</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Analgesics</td>
<td class="Rrule" align="left">methadone</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">alfentanil, buprenorphine IV and sublingual, fentanyl, oxycodone, sufentanil</td>
<td class="Rrule" align="left">
<span class="Bold">Methadone:</span> The potential increase in plasma concentrations of methadone when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Fentanyl:</span> The potential increase in plasma concentrations of fentanyl when coadministered with itraconazole may increase the risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Sufentanil:</span> No human pharmacokinetic data of an interaction with itraconazole are available. <span class="Italics">In vitro</span> data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with itraconazole.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">disopyramide, dofetilide, dronedarone, quinidine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">digoxin</td>
<td class="Rrule" align="left">
<span class="Bold">Disopyramide, dofetilide, dronedarone, quinidine:</span> The potential increase in plasma concentrations of these drugs when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antibacterials</td>
<td class="Rrule" align="left">telithromycin, in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></td>
<td class="Rrule" align="left">rifabutin</td>
<td class="Rrule" align="left">telithromycin</td>
<td class="Rrule" align="left">
<span class="Bold">Telithromycin:</span> The potential increase in plasma concentrations of telithromycin in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>. <br><span class="Bold">Rifabutin:</span> See also under '<a href="#decrease">Drugs that may decrease itraconazole plasma concentrations</a>'.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticoagulants and Antiplatelet Drugs</td>
<td class="Rrule" align="left">ticagrelor</td>
<td class="Rrule" align="left">apixaban, <br>rivaroxaban</td>
<td class="Rrule" align="left">coumarins, <br>cilostazol, <br>dabigatran</td>
<td class="Rrule" align="left">
<span class="Bold">Ticagrelor:</span> The potential increase in plasma concentrations of ticagrelor may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.<br><span class="Bold">Coumarins:</span> Itraconazole may enhance the anticoagulant effect of coumarin-like drugs, such as warfarin.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticonvulsants</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">carbamazepine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Carbamazepine:</span><span class="Italics"> In vivo</span> studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of itraconazole and carbamazepine may inhibit the metabolism of carbamazepine. See also under '<a href="#decrease">Drugs that may decrease itraconazole plasma concentrations</a>'.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antidiabetics</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">repaglinide, saxagliptin</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antihelmintics and Antiprotozoals</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">praziquantel</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimigraine Drugs</td>
<td class="Rrule" align="left">ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">eletriptan</td>
<td class="Rrule" align="left">
<span class="Bold">Ergot Alkaloids:</span> The potential increase in plasma concentrations of ergot alkaloids when coadministered with itraconazole may increase the risk of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>, ie. a risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> potentially leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antineoplastics</td>
<td class="Rrule" align="left">irinotecan</td>
<td class="Rrule" align="left">axitinib, <br>dabrafenib, <br>dasatinib, <br>ibrutinib, <br>nilotinib, <br>sunitinib</td>
<td class="Rrule" align="left">bortezomib, <br>busulphan, <br>docetaxel, <br>erlotinib, <br>imatinib, <br>ixabepilone, <br>lapatinib, <br>ponatinib, <br>trimetrexate, <br>vinca alkaloids</td>
<td class="Rrule" align="left">
<span class="Bold">Irinotecan:</span> The potential increase in plasma concentrations of irinotecan when coadministered with itraconazole may increase the risk of potentially fatal adverse events.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Antipsychotics, Anxiolytics and Hypnotics</td>
<td class="Rrule" align="left">lurasidone, oral midazolam, pimozide, triazolam</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone</td>
<td class="Rrule" align="left">
<span class="Bold">Midazolam, triazolam</span>: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Pimozide:</span> The potential increase in plasma concentrations of pimozide when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>. </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antivirals</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">simeprevir</td>
<td class="Rrule" align="left">maraviroc, indinavir, ritonavir, saquinavir</td>
<td class="Rrule" align="left">
<span class="Bold">Indinavir, ritonavir:</span> See also under '<a href="#increase">Drugs that may increase itraconazole plasma concentrations</a>'.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Beta Blockers</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">nadolol</td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Calcium Channel Blockers</td>
<td class="Rrule" align="left">felodipine, nisoldipine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">other dihydropyridines, verapamil</td>
<td class="Rrule" align="left">
<span class="Bold">Calcium channel blockers</span> can have a negative inotropic effect which may be additive to those of itraconazole. The potential increase in plasma concentrations of calcium channel blockers when co-administered with itraconazole may increase the risk of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Dihydropyridines:</span> Concomitant administration of itraconazole may cause several-fold increases in plasma concentrations of dihydropyridines. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> has been reported in patients concomitantly receiving itraconazole and dihydropyridine calcium channel blockers.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cardiovascular Drugs, Miscellaneous</td>
<td class="Rrule" align="left">ranolazine</td>
<td class="Rrule" align="left">aliskiren, <br>sildenafil, for the treatment of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span></td>
<td class="Rrule" align="left">bosentan, <br>riociguat</td>
<td class="Rrule" align="left">
<span class="Bold">Ranolazine:</span> The potential increase in plasma concentrations of ranolazine when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diuretics</td>
<td class="Rrule" align="left">eplerenone</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">
<span class="Bold">Eplerenone:</span> The potential increase in plasma concentrations of eplerenone when coadministered with itraconazole may increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastrointestinal Drugs</td>
<td class="Rrule" align="left">cisapride</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">aprepitant</td>
<td class="Rrule" align="left">
<span class="Bold">Cisapride:</span> The potential increase in plasma concentrations of cisapride when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Immunosuppressants</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">everolimus, temsirolimus</td>
<td class="Rrule" align="left">budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, rapamycin (also known as sirolimus), tacrolimus</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lipid Regulating Drugs</td>
<td class="Rrule" align="left">lovastatin, simvastatin</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">atorvastatin</td>
<td class="Rrule" align="left">The potential increase in plasma concentrations of atorvastatin, lovastatin, and simvastatin when coadministered with itraconazole may increase the risk of skeletal muscle toxicity, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Respiratory Drugs</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">salmeterol</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Urological Drugs</td>
<td class="Rrule" align="left">fesoterodine, in subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <br>solifenacin, in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></td>
<td class="Rrule" align="left">darifenacin, <br>vardenafil</td>
<td class="Rrule" align="left">fesoterodine, <br>oxybutynin, <br>sildenafil, for the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <br>solifenacin, <br>tadalafil, <br>tolterodine</td>
<td class="Rrule" align="left">
<span class="Bold">Fesoterodine:</span> The potential increase in plasma concentrations of the fesoterodine active metabolite may be greater in subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, which may lead to an increased risk of adverse reactions. <br><span class="Bold">Solifenacin:</span> The potential increase in plasma concentrations of solifenacin in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QT prolongation.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Other</td>
<td class="Rrule" align="left">colchicine, in subjects with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></td>
<td class="Rrule" align="left">colchicine, <br>conivaptan, <br>tolvaptan</td>
<td class="Rrule" align="left">cinacalcet</td>
<td class="Rrule" align="left">
<span class="Bold">Colchicine:</span> The potential increase in plasma concentrations of colchicine when coadministered with itraconazole may increase the risk of potentially fatal adverse events. <br><span class="Bold">Conivaptan and Tolvaptan:</span> A safe and effective dose of either conivaptan or tolvaptan has not been established when coadministered with Itraconazole Capsules.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.4"></a><p></p>
<h3>Drugs that may have their plasma concentrations decreased by itraconazole</h3>
<p class="First">Coadministration of itraconazole with the NSAID meloxicam may decrease the plasma concentration of meloxicam. It is recommended that meloxicam be used with caution when coadministered with itraconazole, and its effects or side effects be monitored. It is recommended that the dosage of meloxicam, if coadministered with itraconazole, be adjusted if necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.5"></a><p></p>
<h3>Pediatric Population</h3>
<p class="First">Interaction studies have only been performed in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Itraconazole showed no evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels up to 80 mg/kg/day (approximately 10x the maximum recommended human dose [MRHD]). Male rats treated with 25 mg/kg/day (3.1× MRHD) had a slightly increased incidence of soft tissue <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>. These <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> may have been a consequence of <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, which is a response of rats, but not dogs or humans, to chronic itraconazole administration. Female rats treated with 50 mg/kg/day (6.25× MRHD) had an increased incidence of squamous cell carcinoma of the lung (2/50) as compared to the untreated group. Although the occurrence of squamous cell carcinoma in the lung is extremely uncommon in untreated rats, the increase in this study was not statistically significant.</p>
<p>Itraconazole produced no mutagenic effects when assayed in DNA repair test (unscheduled DNA synthesis) in primary rat hepatocytes, in Ames tests with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (6 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) and <span class="Italics">Escherichia coli</span>, in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> gene mutation tests, in a sex-linked recessive lethal mutation (<span class="Italics">Drosophila melanogaster</span>) test, in chromosome aberration tests in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, in a cell transformation test with C3H/10T½ C18 mouse embryo fibroblasts cells, in a dominant lethal mutation test in male and female mice, and in micronucleus tests in mice and rats.</p>
<p>Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels of up to 40 mg/kg/day (5× MRHD), even though parental toxicity was present at this dosage level. More severe signs of parental toxicity, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, were present in the next higher dosage level, 160 mg/kg/day (20× MRHD).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.9.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats at dosage levels of approximately 40–160 mg/kg/day (5–20× MRHD), and in mice at dosage levels of approximately 80 mg/kg/day (10× MRHD). Itraconazole has been shown to cross the placenta in a rat model. In rats, the <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> consisted of major skeletal defects; in mice, it consisted of <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephaloceles</span> and/or macroglossia.</p>
<p>There are no studies in pregnant women. Itraconazole should be used for the treatment of systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in pregnancy only if the benefit outweighs the potential risk.</p>
<p>Itraconazole should not be administered for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> to pregnant patients or to women contemplating pregnancy. Itraconazole should not be administered to women of childbearing potential for the treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span> unless they are using effective measures to prevent pregnancy and they begin therapy on the second or third day following the onset of menses. Effective contraception should be continued throughout itraconazole therapy and for 2 months following the end of treatment.</p>
<p>During post-marketing experience, cases of congenital abnormalities have been reported. (See<a href="#AR_pme"> ADVERSE REACTIONS: Post-marketing Experience</a>.)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.10"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Itraconazole is excreted in human milk; therefore, the expected benefits of itraconazole therapy for the mother should be weighed against the potential risk from exposure of itraconazole to the infant. The U.S. Public Health Service Centers for Disease Control and Prevention advises HIV-infected women not to breast-feed to avoid potential transmission of HIV to uninfected infants.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.11"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The efficacy and safety of itraconazole have not been established in pediatric patients.</p>
<p>The long-term effects of itraconazole on bone growth in children are unknown. In three toxicology studies using rats, itraconazole induced bone defects at dosage levels as low as 20 mg/kg/day (2.5× MRHD). The induced defects included reduced bone plate activity, thinning of the zona compacta of the large bones, and increased bone fragility. At a dosage level of 80 mg/kg/day (10× MRHD) over 1 year or 160 mg/kg/day (20× MRHD) for 6 months, itraconazole induced small tooth pulp with hypocellular appearance in some rats.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.12"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Itraconazole Capsules did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. It is advised to use Itraconazole Capsules in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported in elderly patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see<a href="#BOX_DI"> BOXED WARNING: Drug Interactions</a>,<a href="#con_DI"> CONTRAINDICATIONS: Drug Interactions </a>and<a href="#DI"> PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.13"></a><p></p>
<h2>HIV-Infected Patients</h2>
<p class="First">Because hypochlorhydria has been reported in HIV-infected individuals, the absorption of itraconazole in these patients may be decreased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.14"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The exposure of itraconazole may be lower in some patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be exercised when itraconazole is administered in this patient population and dose adjustment may be needed. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations </a>and<a href="#DA"> DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.15"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Caution should be exercised when this drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with Itraconazole Capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4.</p>
<p>In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with itraconazole is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations </a>and<a href="#DA"> DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Itraconazole has been associated with rare cases of serious hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. The risks and benefits of itraconazole use should be reassessed. (See<a href="#war_he"> WARNINGS: Hepatic Effects </a>and<a href="#pre_Hepatotoxicity"> PRECAUTIONS: Hepatotoxicity </a>and<a href="#Information"> Information for Patients</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Adverse Events in the Treatment of Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h2>
<p class="First">Adverse event data were derived from 602 patients treated for systemic fungal disease in U.S. clinical trials who were immunocompromised or receiving multiple concomitant medications. Treatment was discontinued in 10.5% of patients due to adverse events. The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). The table lists adverse events reported by at least 1% of patients.</p>
<table width="90%">
<caption><span>Table 2:	Clinical Trials of Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span>: Adverse Events Occurring with an Incidence of Greater than or Equal to 1%</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Body System/Adverse Event</th>
<th class="Lrule Rrule" align="center">Incidence (%) (N=602)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Gastrointestinal</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">11</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Body as a Whole</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Lrule Rrule" align="center">4</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Skin and Appendages</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Central/Peripheral Nervous System</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Psychiatric</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Cardiovascular</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Metabolic/Nutritional</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Urinary System</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Liver and Biliary System</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic Function Abnormal</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="Bold">Reproductive System, Male</span></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
</tbody>
</table>
<p>Adverse events infrequently reported in all studies included <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and male <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Adverse Events Reported in Toenail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> Clinical Trials</h2>
<p class="First">Patients in these trials were on a continuous dosing regimen of 200 mg once daily for 12 consecutive weeks.</p>
<p>The following adverse events led to temporary or permanent discontinuation of therapy.</p>
<table width="90%">
<caption><span>Table 3:	Clinical Trials of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the Toenail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Adverse Event</th>
<th class="Rrule" align="center">Incidence (%)<br>Itraconazole (N=112)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Elevated Liver Enzymes (greater than twice the upper limit of normal)</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Rrule" align="center">1</td>
</tr>
</tbody>
</table>
<p>The following adverse events occurred with an incidence of greater than or equal to 1% (N=112): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>: 10%; <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>: 9%; <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>: 8%; <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, injury: 7%; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>: 4%; <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, liver function abnormality, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>: 3%; appetite increased, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, abnormal dreaming: 2%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Adverse Events Reported in Fingernail <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> Clinical Trials</h2>
<p class="First">Patients in these trials were on a pulse regimen consisting of two 1-week treatment periods of 200 mg twice daily, separated by a 3-week period without drug.</p>
<p>The following adverse events led to temporary or permanent discontinuation of therapy.</p>
<table width="90%">
<caption><span>Table 4:	Clinical Trials of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span> of the Fingernail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="bottom">Adverse Event</th>
<th class="Rrule" align="center">Incidence (%)<br>Itraconazole (N=37)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></td>
<td class="Rrule" align="center">3</td>
</tr>
</tbody>
</table>
<p>The following adverse events occurred with an incidence of greater than or equal to 1% (N=37): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>: 8%; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>: 5%; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, injury: 3%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Adverse Events Reported from Other Clinical Trials</h2>
<p class="First">In addition, the following adverse drug reaction was reported in patients who participated in Itraconazole Capsules clinical trials: <span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>.</p>
<p>The following is a list of additional adverse drug reactions associated with itraconazole that have been reported in clinical trials of SPORANOX<span class="Sup">®</span> (itraconazole) Oral Solution and itraconazole IV excluding the adverse reaction term "<span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span>" which is specific to the injection route of administration:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>;</p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>;</p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>;</p>
<p><span class="Italics">Investigations:</span> <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, blood urea increased, gamma-glutamyltransferase increased, <span class="product-label-link" type="condition" conceptid="4042234" conceptname="Abnormal urinalysis">urine analysis abnormal</span>;</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>;</p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>;</p>
<p><span class="Italics">Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>;</p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>;</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>;</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AR_pme"></a><a name="section-9.5"></a><p></p>
<h2>Post-marketing Experience</h2>
<p class="First">Adverse drug reactions that have been first identified during post-marketing experience with itraconazole (all formulations) are listed in the table below. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</p>
<table width="100%">
<caption><span>Table 5:	Postmarketing Reports of Adverse Drug Reactions</span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Blood and Lymphatic System Disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>; anaphylactic, anaphylactoid and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>, including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span> and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Ear and Labyrinth Disorders:</span></td>
<td class="Rrule" align="left">Transient or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Hepatobiliary Disorders:</span></td>
<td class="Rrule" align="left">Serious hepatotoxicity (including some cases of fatal <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Renal and Urinary Disorders:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General Disorders and Administration Site Conditions:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Investigations:</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood creatine phosphokinase</span> increased</td>
</tr>
</tbody>
</table>
<p>There is limited information on the use of itraconazole during pregnancy. Cases of congenital abnormalities including skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations have been reported during post-marketing experience. A causal relationship with itraconazole has not been established. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations</a>,<a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a>,<a href="#WARNINGS"> WARNINGS</a>, and<a href="#DI"> PRECAUTIONS: Drug Interactions </a>for more information.) </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Itraconazole is not removed by dialysis. In the event of accidental overdosage, supportive measures should be employed. Activated charcoal may be given if considered appropriate. In general, adverse events reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been consistent with adverse drug reactions already listed in this package insert for itraconazole. (See <a href="#AR">ADVERSE REACTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Itraconazole Capsules should be taken with a full meal to ensure maximal absorption. Itraconazole Capsules must be swallowed whole.</p>
<p>Itraconazole Capsules are a different preparation than SPORANOX<span class="Sup">®</span> (itraconazole) Oral Solution and should not be used interchangeably.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">Blastomycosis</span> and <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">Histoplasmosis</span></h2>
<p class="First">The recommended dose is 200 mg once daily (2 capsules). If there is no obvious improvement, or there is evidence of progressive fungal disease, the dose should be increased in 100-mg increments to a maximum of 400 mg daily. Doses above 200 mg/day should be given in two divided doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">Aspergillosis</span></h2>
<p class="First">A daily dose of 200 to 400 mg is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Treatment in Life-Threatening Situations</h2>
<p class="First">In life-threatening situations, a loading dose should be used.</p>
<p>Although clinical studies did not provide for a loading dose, it is recommended, based on pharmacokinetic data, that a loading dose of 200 mg (2 capsules) three times daily (600 mg/day) be given for the first 3 days of treatment.</p>
<p>Treatment should be continued for a minimum of three months and until clinical parameters and laboratory tests indicate that the active <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> has subsided. An inadequate period of treatment may lead to recurrence of active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Itraconazole Capsules and SPORANOX<span class="Sup">®</span> (itraconazole) Oral Solution should not be used interchangeably. Only the oral solution has been demonstrated effective for oral and/or <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span></h2>
<p class="First">Toenails with or without fingernail involvement: The recommended dose is 200 mg (2 capsules) once daily for 12 consecutive weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">Onychomycosis</span></h2>
<p class="First">Fingernails only: The recommended dosing regimen is 2 treatment pulses, each consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week. The pulses are separated by a 3-week period without itraconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.6"></a><p></p>
<h2>Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution should be exercised when this drug is administered in this patient population. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations </a>and<a href="#PRECAUTIONS"> PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.7"></a><p></p>
<h2>Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Limited data are available on the use of oral itraconazole in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Caution should be exercised when this drug is administered in this patient population. (See<a href="#CP_SP"> CLINICAL PHARMACOLOGY: Special Populations</a>,<a href="#WARNINGS"> WARNINGS</a>, and<a href="#PRECAUTIONS"> PRECAUTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Itraconazole Capsules are available containing 100 mg of itraconazole, with a blue opaque cap and pink transparent body, imprinted with "PP 100." The capsules are supplied in bottles of 30 capsules (NDC 10147-1700-3) and in the <span class="Italics">DosingPak</span> containing 7 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs × 4 capsules each (NDC 10147-1700-7).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at controlled room temperature 15°–25°C (59°–77°F). Protect from light and moisture.</p>
<p>Keep out of reach of children.</p>
<p>For more information call 1-800-667-8570.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Revised May 2015</p>
<p>Product of Ireland</p>
<p>Capsule contents manufactured by:<br>Janssen Pharmaceutica. NV.<br>Olen, Belgium</p>
<p>Manufactured by:<br>JOLLC, Gurabo, Puerto Rico 00778</p>
<p>Manufactured for:<br>Patriot Pharmaceuticals, LLC<br>Horsham, PA 19044</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Itraconazole Capsules 100 mg</span></p>
<p><span class="Bold">This summary contains important information about Itraconazole</span>. This information is for patients who have been prescribed Itraconazole to treat fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span>.<span class="Bold"> If your doctor prescribed Itraconazole for medical problems other than fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span>, ask your doctor if there is any information in this summary that does not apply to you. </span>Read this information carefully each time you start to use Itraconazole. This information does not take the place of discussion between you and your doctor. Only your doctor can decide if Itraconazole is the right treatment for you. If you do not understand some of this information or have any questions, talk with your doctor or pharmacist.</p>
<p><a name="mostimportant"></a><span class="Bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT ITRACONAZOLE?</span></p>
<p>Itraconazole is used to treat fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span>. However, Itraconazole is not for everyone.<span class="Bold"> Do not take Itraconazole for fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span> if you have had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. You should not take Itraconazole if you are taking certain medicines that could lead to serious or life-threatening medical problems. </span>(See "<a href="#whoshouldnottake">Who Should Not Take Itraconazole?</a>" below.)</p>
<p>If you have had heart, lung, liver, kidney or other serious health problems, ask your doctor if it is safe for you to take Itraconazole.</p>
<p><span class="Bold">WHAT HAPPENS IF I HAVE A FUNGAL <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">NAIL INFECTION</span>?</span></p>
<p>Anyone can have a fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>, but it is usually found in adults. When a fungus infects the tip or sides of a nail, the infected part of the nail may turn yellow or brown. If not treated, the fungus may spread under the nail towards the cuticle. If the fungus spreads, more of the nail may change color, may become thick or brittle, and the tip of the nail may become raised. In some patients, this can cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>.</p>
<p><span class="Bold">WHAT IS ITRACONAZOLE?</span></p>
<p>Itraconazole is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the toenails and fingernails. It is also used to treat some types of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in other areas of your body. We do not know if Itraconazole works in children with fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span> or if it is safe for children to take.</p>
<p>Itraconazole comes in the form of capsules and liquid (oral solution). The capsule and liquid forms work differently, so you should not use one in place of the other. This Patient Information discusses only the capsule form of Itraconazole. You will get these capsules in a medicine bottle or an Itraconazole<span class="Italics"> DosingPak</span>. The<span class="Italics"> DosingPak </span>contains 28 capsules for treatment of your fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>.</p>
<p>Itraconazole goes into your bloodstream and travels to the source of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> underneath the nail so that it can fight the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> there. Improved nails may not be obvious for several months after the treatment period is finished because it usually takes about 6 months to grow a new fingernail and 12 months to grow a new toenail.</p>
<p><a name="whoshouldnottake"></a><span class="Bold">WHO SHOULD NOT TAKE ITRACONAZOLE?</span></p>
<p>Itraconazole is not for everyone. Your doctor will decide if Itraconazole is the right treatment for you.<span class="Bold"> Some patients should not take Itraconazole because they may have certain health problems or may be taking certain medicines that could lead to serious or life-threatening medical problems. </span></p>
<p>Tell your doctor and pharmacist the name of all the prescription and non-prescription medicines you are taking, including dietary supplements and herbal remedies. Also tell your doctor about any other medical conditions you have had, especially heart, lung, liver or kidney conditions; or if you have <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, or have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to itraconazole or any other antifungal medicines.</p>
<p><span class="Bold">Never </span>take Itraconazole if you:</p>
<ul class="Disc">
<li>have had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</li>
<li>are taking any of the medicines listed below. Dangerous or even life-threatening side effects could result:<ul class="Disc">
<li>cisapride (such as Propulsid®) </li>
<li>colchicine (such as Colcrys™) [if you also have pre-existing kidney or liver impairment]</li>
<li>disopyramide (such as Norpace<span class="Sup">®</span>)</li>
<li>dofetilide (such as Tikosyn™)</li>
<li>dronedarone (such as Multaq<span class="Sup">®</span>)</li>
<li>eplerenone (such as Inspra<span class="Sup">®</span>)</li>
<li>ergot alkaloids (such as Migranal<span class="Sup">®</span>, Ergonovine, Cafergot<span class="Sup">®</span>, Methergine<span class="Sup">®</span>)</li>
<li>felodipine (such as Plendil<span class="Sup">®</span>)</li>
<li>fesoterodine (such as Toviaz<span class="Sup">®</span>) [if you also have pre-existing kidney or liver impairment]</li>
<li>irinotecan (such as Camptosar<span class="Sup">®</span>)</li>
<li>lovastatin (such as Mevacor<span class="Sup">®</span>, Advicor<span class="Sup">®</span>, Altocor™)</li>
<li>lurasidone (such as Latuda<span class="Sup">®</span>)</li>
<li>methadone (such as Dolophine<span class="Sup">®</span>)</li>
<li>midazolam (such as Versed<span class="Sup">®</span>)</li>
<li>nisoldipine (such as Sular<span class="Sup">®</span>)</li>
<li>pimozide (such as Orap<span class="Sup">®</span>)</li>
<li>quinidine (such as Cardioquin<span class="Sup">®</span>, Quinaglute<span class="Sup">®</span>, Quinidex<span class="Sup">®</span>)</li>
<li>ranolazine (such as Ranexa<span class="Sup">®</span>)</li>
<li>simvastatin (such as Zocor<span class="Sup">®</span>)</li>
<li>solifenacin (such as Vesicare®) [if you also have pre-existing kidney or liver impairment] </li>
<li>telithromycin (such as Ketek®) [if you also have pre-existing kidney or liver impairment] </li>
<li>ticagrelor (such as Brilinta®) </li>
<li>triazolam (such as Halcion<span class="Sup">®</span>)</li>
</ul>
</li>
<li>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to itraconazole.</li>
</ul>
<p>Taking Itraconazole with certain other medicines may lead to serious or life-threatening medical problems. Tell your doctor and pharmacist the name of all the prescription and non-prescription medicines you are taking, including dietary supplements and herbal remedies. Your doctor will decide if Itraconazole is the right treatment for you.</p>
<p><span class="Bold">WHAT SHOULD I KNOW ABOUT ITRACONAZOLE AND PREGNANCY OR BREAST FEEDING?</span></p>
<p>Never take Itraconazole if you have a fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span> and are pregnant or planning to become pregnant within 2 months after you have finished your treatment.</p>
<p>If you are able to become pregnant, you should use effective birth control during Itraconazole treatment and for 2 months after finishing treatment. Ask your doctor about effective types of birth control.</p>
<p>If you are breast-feeding, talk with your doctor about whether you should take Itraconazole.</p>
<p><span class="Bold">HOW SHOULD I TAKE ITRACONAZOLE?</span></p>
<p>Always take Itraconazole Capsules during or right after a full meal.</p>
<p>Your doctor will decide the right dose for you. Depending on your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, you will take Itraconazole once a day for 12 weeks, or twice a day for 1 week in a "pulse" dosing schedule. You will receive either a bottle of capsules or a<span class="Italics"> DosingPak</span>. Do not skip any doses. Be sure to finish all your Itraconazole as prescribed by your doctor.</p>
<p>If you have ever had liver problems, your doctor should do a blood test to check your condition. If you haven't had liver problems, your doctor may recommend blood tests to check the condition of your liver because patients taking Itraconazole can develop liver problems.</p>
<p>Itraconazole can sometimes cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or blurred/<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>. If you have these symptoms, do not drive or use machines.</p>
<p>If you forget to take or miss doses of Itraconazole, ask your doctor what you should do with the missed doses.</p>
<p><span class="Bold">THE ITRACONAZOLE <span class="Italics">DosingPak</span></span></p>
<p>If you use the<span class="Italics"> DosingPak</span>, you will take Itraconazole for 1 week and then take no Itraconazole for the next 3 weeks before repeating the 1-week treatment. This is called "pulse dosing." The Itraconazole<span class="Italics"> DosingPak </span>contains enough medicine for one "pulse" (1 week of treatment).</p>
<p>The Itraconazole<span class="Italics"> DosingPak </span>comes with special instructions. It contains 7 pouches-one for each day of treatment. Inside each pouch is a card containing 4 capsules. Looking at the back of the card, fold it back along the dashed line and peel away the backing so that you can remove 2 capsules.</p>
<ul class="Disc">
<li>Take 2 capsules in the morning and 2 capsules in the evening. This means you will take 4 capsules a day for 7 days. At the end of 7 days, you will have taken all of the capsules in the<span class="Italics"> DosingPak </span>box.</li>
<li>After you finish the<span class="Italics"> DosingPak</span>, do not take any Itraconazole for the next 3 weeks. Even though you are not taking any capsules during this time, Itraconazole keeps working inside your nails to help fight the <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>.</li>
<li>You will need more than one "pulse" to treat your fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>. When your doctor prescribes another pulse treatment, be sure to get your refill before the end of week 4.</li>
</ul>
<table width="100%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="7%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="15">Itraconazole Pulse Dosing</th></tr>
<tr class="Botrule"><th class="Lrule Rrule" align="center" colspan="15">Take 2 Itraconazole capsules twice a day for 1 week</th></tr>
<tr class="Botrule">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center" colspan="2">Day 1</th>
<th class="Lrule" align="center" colspan="2">Day 2</th>
<th class="Lrule" align="center" colspan="2">Day 3</th>
<th class="Lrule" align="center" colspan="2">Day 4</th>
<th class="Lrule" align="center" colspan="2">Day 5</th>
<th class="Lrule" align="center" colspan="2">Day 6</th>
<th class="Lrule Rrule" align="center" colspan="2">Day 7</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
<th class="Rrule" align="center">AM</th>
<th class="Rrule" align="center">PM</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">Week 1</span></td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
<td class="Rrule" align="center">//</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">Week 2</span></td>
<td class="Rrule" align="center" colspan="14" rowspan="3" valign="middle">
<span class="Bold">For the next 3 weeks, do not take any Itraconazole capsules</span>. 										<br><br>Remember to get a refill before the end of Week 4 when your doctor prescribes another <span class="Italics">DosingPak</span>.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center"><span class="Bold">Week 3</span></td></tr>
<tr class="Last"><td class="Lrule Rrule" align="center"><span class="Bold">Week 4</span></td></tr>
</tbody>
</table>
<p><span class="Bold">WHAT ARE THE POSSIBLE SIDE EFFECTS OF ITRACONAZOLE?</span></p>
<p>The most common side effects include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and digestive system problems (such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>).</p>
<p><span class="Bold">Stop Itraconazole and call your doctor or get medical assistance right away </span>if you have a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face. Very rarely, an oversensitivity to sunlight, a <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span> in the limbs or a severe <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span> can occur. If any of these symptoms occur, stop taking Itraconazole and contact your doctor.</p>
<p><span class="Bold">Stop Itraconazole and call your doctor right away </span>if you develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>; have unusual <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your feet, ankles or legs; suddenly gain weight; are unusually tired; <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up white or pink <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span>; have unusual fast heartbeats; or begin to wake up at night. In rare cases, patients taking Itraconazole could develop serious heart problems, and these could be warning signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p><span class="Bold">Stop Itraconazole and call your doctor right away </span>if you become unusually tired; lose your appetite; or develop <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, a yellow color to your skin or eyes, or dark colored urine or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools (bowel movements). In rare cases, patients taking Itraconazole could develop serious liver problems and these could be warning signs.</p>
<p><span class="Bold">Stop Itraconazole and call your doctor right away </span>if you experience any <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> symptoms. In very rare cases, patients taking Itraconazole have reported temporary or permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>.</p>
<p><span class="Bold">Call your doctor right away </span>if you develop <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your extremities (hands or feet), if your vision gets blurry or you see double, if you hear a ringing in your ears, if you lose the ability to control your urine or urinate much more than usual.</p>
<p>Additional possible side effects include <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">painful joints</span>, unpleasant taste, or <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>. These are not all the side effects of Itraconazole. Your doctor or pharmacist can give you a more complete list.</p>
<p><span class="Bold">WHAT SHOULD I DO IF I TAKE AN <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span> OF ITRACONAZOLE?</span></p>
<p>If you think you took too much Itraconazole, call your doctor or local poison control center, or go to the nearest hospital emergency room right away.</p>
<p><span class="Bold">HOW SHOULD I STORE ITRACONAZOLE?</span></p>
<p>Keep all medicines, including Itraconazole, out of the reach of children.</p>
<p>Store Itraconazole Capsules and the<span class="Italics"> DosingPak </span>at room temperature in a dry place away from light.</p>
<p><span class="Bold">GENERAL ADVICE ABOUT ITRACONAZOLE</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Itraconazole for a condition for which it was not prescribed. Do not give Itraconazole to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about Itraconazole. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Itraconazole that is written for health professionals or you can call 1-800-667-8570.</p>
<p>This patient information has been approved by the U.S. Food and Drug Administration.</p>
<p>Revised May 2015</p>
<p>Product of Ireland</p>
<p>Manufactured by:<br>JOLLC, Gurabo, Puerto Rico 00778</p>
<p>Manufactured for:<br>Patriot Pharmaceuticals, LLC<br>Horsham, PA 19044</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg Carton</h1>
<p class="First"><span class="Bold">NDC 10147-1700-7</span></p>
<p><span class="Bold">Contains 7 pouches x<br>4 capsules each</span></p>
<p><span class="Bold">100 mg<br>Itraconazole</span><br>Capsules<br><span class="Italics">DosingPak</span></p>
<p><span class="Bold">Each capsule contains: </span>itraconazole 100 mg</p>
<p><span class="Bold">Dosage: </span>See accompanying product literature.</p>
<p>Store at controlled room temperature<br>15°-25°C (59°-77°F).</p>
<p>Protect from light and moisture.</p>
<p>Keep out of reach of children.</p>
<p>Rx only</p>
<p>Capsule contents manufactured by:<br>Janssen Pharmaceutica N.V.<br>Olen Belgium</p>
<p>Manufactured by:<br>JOLLC<br>Gurabo, Puerto Rico 00778</p>
<p>Manufactured for:<br>Patriot Pharmaceuticals, LLC<br>Horsham, PA 19044</p>
<p><span class="Bold">PATRIOT</span><br>PHARMACEUTICALS LLC</p>
<div class="Figure"><img alt="Principal Display Panel - 100 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6242b7ad-eaa0-a524-b6e0-ec33e63407db&amp;name=itraconazole-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ITRACONAZOLE 		
					</strong><br><span class="contentTableReg">itraconazole capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10147-1700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ITRACONAZOLE</strong> (ITRACONAZOLE) </td>
<td class="formItem">ITRACONAZOLE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 22</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue opaque) , PINK (pink transparent) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PP;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10147-1700-3</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10147-1700-7</td>
<td class="formItem">7  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">4  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020083</td>
<td class="formItem">02/01/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Patriot Pharmaceuticals
							(178220385)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutical</td>
<td class="formItem"></td>
<td class="formItem">985421372</td>
<td class="formItem">API MANUFACTURE(10147-1700)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica, NV</td>
<td class="formItem"></td>
<td class="formItem">374747970</td>
<td class="formItem">API MANUFACTURE(10147-1700)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica, NV</td>
<td class="formItem"></td>
<td class="formItem">400345888</td>
<td class="formItem">MANUFACTURE(10147-1700)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">JOLLC</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">MANUFACTURE(10147-1700)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>64c522f7-8efc-4064-8e6b-a6c5c4fc9c13</div>
<div>Set id: 6242b7ad-eaa0-a524-b6e0-ec33e63407db</div>
<div>Version: 9</div>
<div>Effective Time: 20150521</div>
</div>
</div> <div class="DistributorName">Patriot Pharmaceuticals</div></p>
</body></html>
